Chitomur
Bladder bioregulator
Chitomur (Bladder bioregulator) is a longevity & bioregulators research compound. Khavinson bladder/urinary-tract bioregulator — proposed to support urothelial function with age.
Chitomur quick facts
| Reported research dose (Injectable) | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~15-30 min |
| Forms | Injectable, Oral |
| Evidence level | Russian studies; limited |
| Other forms available | Oral — dosed differently |
Bladder cytogen — course-based urogenital support. Bladder-directed. People generally arrive here with a specific urinary complaint rather than a longevity plan. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, a urinalysis, and your own night-waking frequency. Run it as an experiment you measure, not a protocol you trust.
How Chitomur works
Khavinson bladder/urinary-tract bioregulator — proposed to support urothelial function with age.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Chitomur
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Chitomur
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Sold for bladder and urinary tract function with age, a genuinely common complaint with few good options. That gap is why this arm of the series sells despite the evidence position.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A bladder-derived peptide complex proposed to support urothelial function.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
- Urinary symptoms respond strongly to expectation — placebo response rates in overactive bladder trials routinely run 30–40%, which is precisely why an uncontrolled report of improvement here carries less weight than it would in most other tissues.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Chitomur actually does
Chitomur is a bladder-derived peptide complex, and it is the only product on any of this site's 12 Khavinson organ pages with an indexed randomized human study under its own trade name. That fact reorders everything below it, so it goes first.
What the preparation is. Not a molecule. A size-fractionated extract of bladder tissue, standardized by total peptide content, with no published sequence, no formula, no exact mass and no computable charge. The defined peptides in the same catalog have all of those — Chonluten is C11H17N3O8 at 319.28 Da, Cardiogen is C18H31N7O9 at 489.50 Da — and those numbers are what let a page argue about membrane crossing, peptidase clearance and dose. None of that arithmetic is available here, and no certificate of analysis can supply it, because sterility, endotoxin and total protein do not identify a mixture.
The route problem, and why this product has the best version of it. The named way into an epithelial cell in this school's work is PEPT1, described as carrying di- and tripeptides — 2 and 3 residues Khavinson 2022. A complex of unstated chain lengths is neither, and 2 and 3 residues is the whole of that range. But the urothelium is unusual: it is the tissue this product is aimed at, and it is bathed from the inside by urine, which is where anything cleared by the kidney ends up. So there is a route to the target that does not require the peptide to be delivered by blood to a deep organ — it requires only that some fragment survive plasma peptidases, pass the glomerulus and reach the bladder lumen. That is a better argument than the pancreatic or thyroid preparations in this catalog can make, and it has never been written down or tested.
What the class proposes once inside. Transcriptional regulation in the target tissue Khavinson 2021. For an undefined mixture that remains an inherited claim rather than a demonstrated one: there is no named molecule here to have a named target.
Cell, rodent, human — and where it stops
The human study, stated in full, because almost nobody selling this has read it. A randomized blind study of the peptide bioregulator Chitomur in aged female patients with overactive bladder, aged 48 to 80, reading out urodynamic parameters and quality of life Gomberg 2013. The abstract reports reduced urgency and fewer episodes of urge incontinence, improvement in bladder condition, and no side effects detected during the study.
Now read the sentence in that abstract that nobody quotes. The authors report that the fall in patients' anxiety about their urinary symptoms became evident 1.5 times faster than the improvement in the symptoms themselves — 1.5x, their number and not this page's. That is the authors' own finding and it is an unusually candid one: the affective response ran ahead of the physical response. In a condition where the symptom is reported by the patient and the distress is the reason they seek treatment, a response that arrives in the feeling before it arrives in the function is the exact shape an expectation effect takes. It does not mean the drug did nothing: a real effect on bladder receptor signaling and an expectation effect are not mutually exclusive. It means the trial's own data contain the signature of the thing a trial is supposed to control for.
What the study does not report. The abstract states no number of participants, no placebo arm, no urodynamic effect size, and no post-void residual volume — which is the safety measurement for any bladder intervention. It is 1 Russian-language paper from 2013, and no independent group has replicated it in the years since. Overactive bladder is also, notoriously, a condition in which inactive treatment performs well in trials, because the endpoints are diaries and questionnaires and because symptoms fluctuate on their own.
The obstacles. (1) 1 unreplicated trial with an unstated sample size is a starting point, not a conclusion. (2) The product tested and the product bought are both undefined mixtures, so nobody can confirm they are the same material. (3) There is no animal or cell work under this trade name to explain the result. (4) The class's outside view is an independent systematic review of 24 randomized trials over 2,245 participants with risk of bias moderate to high and certainty of evidence low to very low, on cognitive rather than urological endpoints Alsulaimani 2021; the older human record invoked for the family used injected thymus and pineal preparations over 6 to 8 years Khavinson 2003, which is a different route, different organs and different products.
What would have to be true, and how you would know it was not
Three predictions, and the first is the only one that can distinguish this product from the way it feels to take it.
1. Run a bladder diary for 3 days, not a memory. Voids per 24 hours, nocturia episodes, urgency episodes, and volume per void from a measuring jug. That is the endpoint the published study used a questionnaire version of, it costs nothing, and it is the only way to see whether the function moved rather than the feeling. Do it for 3 days before the course and 3 days after. Based on the study's own reported pattern, the prediction is specific and it cuts against the product: the subjective improvement will outrun the diary, and if the diary does not move, the diary is the answer.
2. A urinalysis before anything else. Urgency and frequency are the presentation of urinary tract infection, and blood in the urine that a person cannot see is the presentation of bladder cancer, which is more common in older smokers and which presents exactly like this. This site's guidance is to run a urinalysis annually or with any kidney concern, and a new urinary symptom is a kidney concern. Nothing in a peptide mechanism predicts a change in it; it is there to catch the thing that should not be treated with a capsule.
3. Check whether the bladder is even the organ. Nocturia in particular is frequently not a bladder problem: evening fluid and alcohol, untreated sleep apnea, heart failure and poorly controlled blood sugar all produce it. Fructosamine and HbA1c between them cover the glycemic cause and this site retests them every 3 to 4 weeks and every 3 months respectively; in men, PSA is the marker for the prostate cause of the same symptoms and this site checks it at baseline and annually. If one of those is the reason, a bladder peptide cannot fix it and the course will read as a failure of the product when it was a failure of the diagnosis.
What nobody has tested yet
Four things nobody has done, and the first is the most surprising on this page given that a positive trial exists.
1. Nobody has replicated the 2013 study. It is randomized, it reported a positive result, it reported no side effects, and it has sat unreplicated ever since Gomberg 2013. A single placebo-controlled repeat with a bladder diary endpoint and a stated sample size would move this compound further than anything else anybody could do, and it is the cheapest trial in this whole category because the endpoint is a piece of paper.
2. Nobody has published what is in the capsule. Liquid chromatography with tandem mass spectrometry on 1 lot would list chain lengths and identifiable sequences. Without it there is no way to know whether today's product is the material that was trialed in 2013.
3. Nobody has looked in the urine. If any fragment of this preparation is absorbed and cleared renally, it should be detectable in urine by mass spectrometry after a dose. That single experiment would test the luminal-delivery argument above, and it is the only route in this catalog where the target tissue is reachable by a non-invasive sample.
4. Nobody has run it against a drug that works. Antimuscarinics and beta-3 agonists have large randomized trials in overactive bladder with diary endpoints and known side-effect profiles. A head-to-head, or even an add-on design, would tell a buyer something. 0 exist.
Chitomur — its own safety story, not its class's
Three things specific to a bladder product, none of them in the class block.
Visible or invisible blood in the urine ends the conversation about peptides. Hematuria in an adult, particularly a smoker or former smoker over 50, requires evaluation for bladder and kidney cancer — imaging and cystoscopy, not a capsule. This is the one symptom on this page where a delay of months has a measurable cost, and the test that finds it is a urinalysis.
Retention is the failure mode nobody measures. A bladder that empties incompletely causes infection and, if severe, kidney damage — and it can present as frequency and urgency, the same symptoms this product is bought for. Post-void residual volume is measured with a bedside ultrasound in under 5 minutes, and the published study on this product did not report it Gomberg 2013. Anyone whose symptoms worsen on a course, rather than improve, should have it measured rather than continuing.
What the reported absence of side effects is worth. The 2013 study states that no side effects were detected. That is a real observation and it is also 1 study of unstated size in a population of older women, which cannot detect anything uncommon. Outside it there are 0 published adverse events for this product, and with no other human studies there has been no other setting in which one could have been recorded. Animal-tissue origin adds a sourcing question that the synthetic peptides in this catalog do not carry.
Sources read for this page
- Gomberg VG, Ryzhak AP, Lyutov RV. Correction of age related bladder function decrease with peptide geroprotector in women. Advances in Gerontology 2013;26(2):309–314 · PMID 28976156
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
Chitomur — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Chitomur — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Chitomur moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Chitomur in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Chitomur
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Chitomur — frequently asked questions
What is Chitomur?
Chitomur (Bladder bioregulator) is a longevity & bioregulators research compound. Khavinson bladder/urinary-tract bioregulator — proposed to support urothelial function with age.
Is the full Chitomur protocol on this page?
The reported research dose is on this page, along with how Chitomur works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Chitomur?
Chitomur has an approximate half-life of ~15-30 min, which is part of what determines how often it's dosed.
What forms does Chitomur come in?
Chitomur is available as: Injectable, Oral.
What's the evidence behind Chitomur?
Current evidence level: Russian studies; limited. Chitomur is offered for research purposes only and is not an approved medicine.
Chitomur inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Chitomur is used for
Chitomur appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Chitomur is the liver, kidney & gut arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.